Rheumatoid arthritis.
Conditions
Interventions
Intervention 1: Intervention group: The routine DMARDs in addition to 600 milligrams of effervescent of n-acetylcysteine(osve pharmaceutical company), twice daily for two months. Before intervention,
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Rheumatoid arthritis patients with a DAS28-ESR score>=2.6 No history of consuming antioxidant supplements within last 2 months No change of the type and dose of patient's drugs in the last 1 month No recent infectious disease Patients that are under treatment with DMARDs
Exclusion criteria
Exclusion criteria: Biologic agents therapy in the last 6 months Patients with concurrent autoimmune, rheumatoid disease and gout Using other complementary and alternative medicine Pregnancy and lactation Any addiction to psychotropic agents and opioids Uncontrolled hypertension Active gastrointestinal ulcer History of severe skin allergy Consuming nitroglycerin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL-1, IL-17, DAS28-ESR, patient global assessment. Timepoint: Base, the end of the fourth week, the end of the eighth week. Method of measurement: Serum level, clinical signs, DAS28-ESR questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| ESR, Number of tender joints, number of swollen joints, reduced or increased need for oral or injectable corticosteroids. Timepoint: Baseline, at the end of the fourth week, at the end of the eighth week. Method of measurement: Serum level, clinical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJamshid Salamzadeh
Shahid Beheshti University of Medical Sciences
Outcome results
None listed